TCL Archive IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC March 28, 2014
TCL Archive Particle Therapy Program Would cost $600 million Over 10 Years for 16 Facilities, Clinical Trials December 2, 1977